论文部分内容阅读
肝动脉化疗栓塞术 Transcatheter ArterialChemoembolization(TAE)and intra—arterialinfusion(TAI)治疗原发性和转移性肝癌其疗效已被多数作者肯定。目前已广泛应用于临床。近期疗效满意,远期疗效仍不理想。作者将本院接受肝动脉化疗栓塞治疗的肝癌患者,按生存期不足六个月和超过六个月分成两组,对影响两组生存期的因素进行分析,并讨论如何提高患者生存期。 一般资料
Transcatheter Arterial Chemoembolization (TAE) and intra-arterial linfusion (TAI) treatment of primary and metastatic liver cancer has been confirmed by most authors. Has been widely used in clinical. Satisfactory results in the near future, long-term efficacy is still not ideal. The authors treated patients with hepatocellular carcinoma who underwent transcatheter arterial chemoembolization in our hospital. They were divided into two groups according to the survival period of less than six months and more than six months. The factors affecting the survival time of the two groups were analyzed, and how to improve the survival of patients was discussed. normal information